CIDP

Halozyme Therapeutics announced the European Commission’s approval of argenx’s VYVGART subcutaneous injection, utilizing Halozyme’s ENHANZE drug delivery technology, for chronic inflammatory demyelinating polyneuropathy (CIDP). This approval, based on positive ADHERE trial data, marks a significant advancement for CIDP treatment and expands drug access across Europe. VYVGART, the first targeted IgG Fc-antibody fragment for CIDP, represents a new treatment mechanism in over three decades. The SC injection can be administered by patients, caregivers, or healthcare professionals.